During Thursday’s Current trade, Shares of Exterran Holdings, Inc. (NYSE:EXH), lost -0.61% to $22.65.
Exterran Holdings, Inc. (EXH) declared an update to the planned financing in connection with its formerly declared separation.
In November 2014, Exterran Holdings declared that it intends to separate its international contract operations, international aftermarket services and global fabrication businesses into a standalone, publicly traded company named Exterran Corporation. Upon completion of the spin-off, Exterran Holdings, which will continue to own and operate its contract operations and aftermarket services businesses in the United States, will be renamed Archrock, Inc.
Spin-off Transaction Details and Next Steps
Exterran Holdings has reached financing arrangements for Exterran Corporation and Archrock, Inc. that enable Exterran Holdings to move forward with the separation transaction through an all secured financing structure. As a result, Exterran Holdings anticipates that the spin-off of Exterran Corporation will take place in the fourth quarter 2015. The completion of the spin-off will be subject to completion of a review by the U.S. Securities and Exchange Commission of Exterran Corporation’s Form 10, the receipt of an opinion of counsel as to the tax-free nature of the transaction, the execution of separation and intercompany agreements and final approval of the Exterran Holdings board of directors.
Exterran Holdings, Inc., together with its auxiliaries, provides operations, maintenance, services, and equipment for the oil and natural gas production, processing, and transportation applications.
Shares of PDC Energy Inc (NASDAQ:PDCE), declined -2.11% to $57.66, during its current trading session.
PDC Energy, Inc. (PDCE) declared plans to host a conference call with investors to talk about 2015 third quarter results. Conference call materials will be accessible on the Company’s website,www.pdce.com, at the time of the call.
Conference Call and Webcast:
Date/Time: Thursday, November 5, 2015 at 11:00 a.m. ET
PDC Energy, Inc., an independent exploration and production company, acquires, explores for, develops, and produces crude oil, natural gas, and natural gas liquids in the United States.
Qiagen NV (NASDAQ:QGEN), during its Thursday’s current trading session decreased -0.51% to $25.52.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently declared the launch of a new QIAGEN hereditary disease solution for research labs to accelerate solve rates in diagnostic odyssey cases, while freeing up time and resources by enabling researchers to directly focus on the right causal candidates. The offering comprises QIAGEN’s Biomedical Genomics Workbench, Biomedical Genomics Server Solution, Ingenuity® Variant Analysis™, and HGMD® Human Gene Mutation Database. The new end-to-end solution is rolling out this week at the American Society for Human Genetics (ASHG) Annual Meeting in Baltimore.
“QIAGEN continues to expand our solutions to enable the incredible advances that clinical research labs are making every day, particularly in next-generation sequencing for hereditary diseases,” said Dr. Laura Furmanski, Head of QIAGEN’s Bioinformatics Business Area. “By providing the market’s most comprehensive biomedical content, more than 10 million findings in our QIAGEN Knowledge Base, and the benefits of 16 years of experience in expert curation, we ensure the highest-quality analysis and interpretation - assisting customers move from Sample to Insight.”
QIAGEN’s hereditary disease solution addresses the NGS analysis bottleneck by delivering seamless and highly accurate end-to-end workflows for the identification and interpretation of causal variants in hereditary and rare diseases from NGS data. A laboratory using this new hereditary disease solution can achieve a case solve rate as high as 99%, while significantly reducing the rate of irrelevant variants for follow-up by 94% to 100%. These close to perfect solve rates are not possible using any other bioinformatics solution accessible in the market recently, according to the latest benchmarking study that QIAGEN will present at ASHG. The solution is cost-effective and can handle a high volume of samples (for example, 18,000 whole genomes per year). In addition, the QIAGEN Knowledge Base enables collaborative progress for clinical research labs that share information on hereditary diseases in datasets such as the Allele Frequency Community.
QIAGEN N.V. provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
